Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Tiotropium (9mcg) Inhaler
Therapeutic Category
Asthma, Pulmonary, Respiratory
Dosage Form
Inhaler
Packaging Type
Packaging
200 Metered Dose
Price
₹594/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Tiotropium 9mcg inhaler is a long-acting bronchodilator used for the management of chronic obstructive pulmonary disease (COPD) and chronic bronchitis, improving airflow and respiratory comfort.
It works by blocking muscarinic receptors in the airways, leading to smooth muscle relaxation, prolonged bronchodilation, and reduced airway constriction.
This inhaler is commonly prescribed for maintenance therapy in COPD patients, chronic bronchitis, and emphysema, helping decrease breathlessness, wheezing, and exacerbation frequency.
With proven efficacy, once-daily convenience, and strong clinical acceptance, this formulation enhances a respiratory therapy product portfolio and supports consistent demand in pulmonary care management.
Common side effects may include dry mouth, throat irritation, cough, headache, or mild dizziness. Rarely, urinary retention or cardiovascular effects may occur in sensitive patients.
Tioprime Inhaler is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is used to relieve bronchospasm and improve lung function, as prescribed by a healthcare professional.
For inhalation use only. Use strictly under medical supervision. Not intended for acute bronchospasm relief. Rinse mouth after use to prevent irritation. Keep the inhaler clean and follow proper inhalation technique.
Store below 25°C in a cool, dry place. Protect from direct sunlight and moisture. Keep out of reach of children.
Composition : Formoterol (12mcg) + Tiotropium (18mcg)
Composition : Tiotropium (18mcg)
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
Composition : Formoterol (6mcg) + Fluticasone Propionate (250mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (250mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (500mcg)
Composition : Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Tiotropium inhaler has strong demand in the respiratory and pulmonology segment, making it a high-value chronic care product for pharma distributors, wholesalers, and franchise partners. It is widely used for COPD (chronic obstructive pulmonary disease), chronic bronchitis, and long-term breathing difficulty management, ensuring consistent prescription-driven demand.
Medical distributors and agencies benefit from the growing prevalence of chronic respiratory diseases, especially in polluted and urban areas. Long-acting bronchodilator for COPD maintenance therapy Helps improve airflow and reduce breathlessness Once-daily dosing improves patient compliance Widely prescribed by pulmonologists and chest physicians Strong demand in hospital and specialty clinic prescriptions Essential in long-term respiratory disease management This makes it a premium, high-demand respiratory care product with steady long-term usage.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Tiotropium 9 mcg Inhaler with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from consistent chronic respiratory prescription flow, strong pulmonology demand, repeat monthly usage, and stable year-round turnover in the respiratory segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete respiratory product portfolio access to build a strong presence in the COPD and pulmonology market.